Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Completed
- Conditions
- Pancreatic Cancer Resectable
- Registration Number
- NCT05483257
- Lead Sponsor
- BAIYONG SHEN
- Brief Summary
Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 226
Inclusion Criteria
- Radically resected pancreatic adenocarcinoma (stage I-III)
- Resected tumor tissues and matched blood cells available
- Signed informed consent
Exclusion Criteria
- Pancreatic cancer except pancreatic adenocarcinoma
- Non-radical resection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival (DFS) 2 years Comparison of DFS between patients with specific HLA-I genotypes or not
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ruijin Hospital
🇨🇳Shanghai, Shanghai, China
Ruijin Hospital🇨🇳Shanghai, Shanghai, China